A5003162215- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Colorectal Cancer Screening and Detection
- Tuberculosis Research and Epidemiology
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders
- Diagnosis and treatment of tuberculosis
- Gastric Cancer Management and Outcomes
- Systemic Lupus Erythematosus Research
- Pharmaceutical studies and practices
- Breast Implant and Reconstruction
- Pregnancy and Medication Impact
- Cancer Immunotherapy and Biomarkers
- Liver Diseases and Immunity
- Spondyloarthritis Studies and Treatments
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Reconstructive Surgery and Microvascular Techniques
- Breast Lesions and Carcinomas
- Cytomegalovirus and herpesvirus research
- Gastrointestinal motility and disorders
Ministero della Salute
2021-2025
Ospedale Vincenzo Cervello
2017-2021
University of Messina
2019
University of Palermo
2017-2018
Background: Although endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using lumen-apposing metal stents (LAMS) has become one of the treatments choice for acute cholecystitis (AC) in fragile patients, scant data are available on real-life settings and long-term outcomes. Methods: We performed a multicenter retrospective study including EUS-guided GBD LAMS AC 19 Italian centers from June 2014 to July 2020. The primary outcomes were technical clinical success, secondary rate adverse...
Abstract Background No data on the recently introduced infliximab (IFX) biosimilar SB2 in inflammatory bowel disease (IBD) are available. Methods The Sicilian Prospective Observational Study of Patients With IBD Treated Infliximab Biosimilar is a multicenter, observational, prospective study performed among cohort Network for Inflammatory Bowel Disease. All consecutive patients starting IFX from its introduction Sicily (March 2018) to September 2019 (18 months) were enrolled. Results Two...
Purpose: Bioimpedance data through bioimpedance vector analysis (BIVA) is used to evaluate cellular function and body fluid content. This study aimed (i) identify whether BIVA patters differ according the competitive period (ii) provide specific references for assessing bioelectric properties at start of season in male elite soccer players. Methods: The included 131 players (age: 25.1 ± 4.7 yr, height: 183.4 6.1 cm, weight: 79.3 6.6) registered first Italian division (Serie A). was performed...
BACKGROUNDThe effectiveness of colonoscopy strictly depends on adequate bowel cleansing.Recently, a 1 L polyethylene glycol plus ascorbate (PEG-ASC) solution (Plenvu; Norgine, Harefield, United Kingdom) has been introduced the evidence three phase-3 randomized controlled trials, but it had never tested in real-life. AIMTo assess and tolerability preparation compared to 4 2 L-PEG solutions real-life setting. METHODSAll patients undergoing screening or diagnostic after 4, PEG preparation, were...
Abstract Background and Aim Postoperative recurrence (POR) following ileocolonic resection is a major concern in patients with Crohn's disease (CD). The role of ustekinumab (UST) this setting poorly known. Methods All consecutive CD baseline colonoscopy at 6–12 months from showing POR (Rutgeerts score ≥ i2) who were treated UST after the an available post‐treatment endoscopy, extracted cohort Sicilian Network for Inflammatory Bowel Diseases (SN‐IBD). primary outcome was endoscopic success,...
There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison infliximab [IFX] and adalimumab [ADA] Crohn's disease [CD].Data consecutive patients with CD treated IFX ADA from January 2013 May 2017 were extracted cohort Sicilian Network for Inflammatory Bowel Disease. used propensity score-matching accounting main baseline characteristics TNF-α inhibitor-naïve non-naïve...
Biologically naïve patients with inflammatory bowel disease treated vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre, observational cohort study was performed on the effectiveness and safety of VDZ biologically subjects Crohn's (CD) ulcerative colitis (UC).Data consecutive CD UC from July 2016 to December 2019 were extracted Sicilian Network for Inflammatory Bowel Disease.A total 172 (CD: N = 88; UC: 84; median age 66.0 years) included, a follow-up 58.8...
Background. Despite breast implants have been putting on the market for over 70 years, responsible Competent Authorities medical devices are requiring establishment of implant registries to improve vigilance and post-market surveillance activities. Although data collected during pilot phase not yet representative surgery performed in Italy, authors would share their preliminary results show potential that registry will next future knowledge use implants. Moreover, based experience gained...
Ustekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real-life data are scarce, so aim this study was assess effectiveness and safety ustekinumab an cohort CD patients.Data patients with who started using were extracted from Sicilian Network Inflammatory Bowel Disease. Primary end-points steroid-free clinical remission at 8, 24, 52 weeks therapy reduction C-reactive protein. Secondary response, persistence 12 months, safety.A total 131...
The occurrence of thiopurine-related adverse events (AEs) may complicate the management patients with inflammatory bowel disease (IBD). We aimed to evaluate tolerability thiopurines in a current IBD setting.All consecutive who started treatment azathioprine (AZA) from January 2010 March 2016 were entered prospectively maintained database, and AEs which led permanent discontinuation drug reported.Two hundred fifty three included. Median total follow-up was 32 months (range: 0.2-75 months). At...
There are no head-to-head randomized controlled trials between biologics in Crohn's disease (CD). We aimed to perform a multicenter, real-life comparison of the effectiveness vedolizumab (VDZ) and adalimumab (ADA) CD.Data consecutive patients with CD treated VDZ ADA from January 2016 April 2019 were extracted cohort Sicilian Network for Inflammatory Bowel Disease. The was evaluated at 12, 52 weeks, as failure-free survival end follow up. Propensity score analysis performed using inverse...
Abstract Background and Aim There are few clinical data on Adalimumab (ADA) biosimilars in inflammatory bowel disease. We aimed to perform a multicenter, observational, prospective study safety effectiveness of ADA biosimilar ABP 501 patients with Methods All consecutive from the cohort Sicilian Network for Inflammatory Bowel Disease treated February 2019 2020 were enrolled. Patients divided into three groups: group A, naïve anti‐tumor necrosis factors; B, previously exposed C: switched...